An excellent Prostate Cancer Therapeutics Market research report provides clients with the information on their business scenario with which they can build business strategies to thrive in the market. This makeover can be subjected to the moves of key players or brands which include developments, product launches, joint ventures, mergers and acquisitions that in turn change the view of the global face of the industry. According to this market report, the global market is anticipated to observe a moderately higher growth rate during the forecast period. Prostate Cancer Therapeutics Market report also covers strategic profiling of the major players in the market, all-inclusive analysis of their basic competencies, and hence keeps competitive landscape of the market in front of the client.
 
The large scale Prostate Cancer Therapeutics Market report makes customers or other market participants aware of the problems they may face while operating in this market over a longer period of time. It generally includes major manufacturers, suppliers, distributors, traders, customers, investors, major types, and major applications. The data gathered to prepare this report is based on the data collection modules with large sample sizes. With Prostate Cancer Therapeutics Market report study, businesses can know about the key opportunities in the market and influencing factors which is useful to take business to the highest level.
 
Global Prostate Cancer Therapeutics Market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 8.2% in the above mentioned forecast period and is likely to reach the value USD 21.90 billion by 2029.
 
Download Sample PDF Copy of this Report to understand structure of the complete report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-therapeutics-market
 
Market Definition
 
Prostate cancer is a kind of cancer in which abnormal cells in the prostate gland proliferate and expand uncontrollably. Prostate cancer is the sixth leading cause of death in males, and the eleventh leading cause of death from any disease. Radiation, chemotherapy, hormone therapy, surgery and biological therapy are all options for treating prostate cancer. Prostate cancer is treated and managed with a variety of diagnostic and therapeutic items, including prostatic adenocarcinoma, small cell carcinoma, benign prostatic hyperplasia, and others.
 
Some of the major players operating in the prostate cancer therapeutics market are Johnson & Johnson Private Limited, Astellas Pharma Inc., Ipsen Pharma, Sanofi, Bayer AG, AbbVie Inc., AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd., Myovant Sciences GmbH, Tolmar Pharmaceuticals, Inc., Ferring B.V., Dendreon Pharmaceuticals LLC., and Genentech, Inc., among others.
 
Recent Development
 
  • In January 2021, U.S. Food and Drug Administration (FDA) have approved a new drug named Relugolix which is expected to modify the treatment for advanced prostate cancer. The medicine relugolix (Orgovyx) was found to be more successful at lowering testosterone levels in men with advanced prostate cancer in a substantial clinical trial.  
  • In June 2021, Novartis AG has announced that the U.S. Food and Drug Administration (FDA) have granted Breakthrough Therapy designation (BTD) to 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Breakthrough Therapy designation is given to drugs that are being studied for critical illnesses and show early clinical evidence of a significant improvement over current therapy.
 
 
 
Table of Content:
 
Part 01: Executive Summary
Part 02: Scope of the Report
Part 03: Research Methodology
Part 04: Global Prostate Cancer Therapeutics Market Landscape
Part 05: Pipeline Analysis
Part 06: Global Prostate Cancer Therapeutics Market Sizing
Part 07: Five Forces Analysis
Part 08: Global Prostate Cancer Therapeutics Market Segmentation
Part 09: Customer Landscape
Part 10: Regional Landscape
Part 11: Decision Framework
Part 12: Drivers and Challenges
Part 13: Global Prostate Cancer Therapeutics Market Trends
Part 14: Vendor Landscape
Part 15: Vendor Analysis
Part 16: Appendix
 
Browse Trending Reports:
 
 
 
 
 
About Data Bridge Market Research:
 
An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.
 
Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.
 
Contact Us: -
 
Data Bridge Market Research
 
US: +1 888 387 2818
 
United Kingdom: +44 208 089 1725
 
Hong Kong: +852 8192 7475